Vivalyx has developed Vivalyx Omnisol, a fully synthetic liquid designed for organ perfusion at body temperature and for cold and warm perfusion as well as static cold storage. The company’s technology aims to revitalize donor organs to increase their vitality and the number of organs available for life‑saving transplants. Vivalyx plans to use newly raised funds to finance necessary clinical trials to achieve regulatory clearance and to begin commercialization. The startup was founded by Dr. Andreas Schumacher, Dr. Benedict Doorschodt, Prof. Dr. René Tolba, PD. Dr. Christian Bleilevens, Prof. Dr. Malte Brettel and Marius Rosenberg. Vivalyx is based in Aachen, Germany. The article does not disclose revenue or user metrics.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

May 2024